New findings could help identify patients likely to become resistant to anti-cancer drugs and aid exploring different ways to ...

Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...

Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with ...

For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with ...